	US 12,448,423 B2
	Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
Matthew J. Bernett, Monrovia, CA (US); John R. Desjarlais, Pasadena, CA (US); Rajat Varma, Monrovia, CA (US); Gregory Moore, Azusa, CA (US); Juan Diaz, Anaheim Hills, CA (US); Alex Nisthal, Monrovia, CA (US); Ke Liu, Glendora, CA (US); Rumana Rashid, Temple City, CA (US); and Eric Chang, Walnut, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Monrovia, CA (US)
Filed on Oct. 18, 2022, as Appl. No. 17/968,611.
Application 17/968,611 is a division of application No. 16/724,118, filed on Dec. 20, 2019, granted, now 11,618,776.
Claims priority of provisional application 62/783,106, filed on Dec. 20, 2018.
Prior Publication US 2023/0340053 A1, Oct. 26, 2023
Int. Cl. A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/54 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/5443 (2013.01) [A61P 35/00 (2018.01); C07K 16/2851 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01)]

14 Claims

1. A targeted molecule comprising:

an NKG2D antigen binding domain (ABD), said ABD comprising a variable heavy chain domain (“VH domain”) and a variable light chain domain (“VL domain”), wherein said VH domain has at least 95% amino acid sequence identity with SEQ ID NO: 1040 and said VL domain has at least 95% amino acid sequence identity with SEQ ID NO: 1041.